^
Association details:
| Biomarker: | ALCAM elevation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) + abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
Published date:
06/11/2022
Excerpt:
In addition, ALCAM serum levels were measured in 101 Abiraterone (ABI) and 100 Docetaxel (DOC)-treated mCRPC patients' baseline samples….Furthermore, higher baseline ALCAM levels were associated with poor survival in ABI- but not in DOC-treated patients...In the ENZA and ABI cohort, Kaplan-Meier OS curves revealed that higher baseline ALCAM levels (>146.6 and >143.1 ng/mL by ROC cut-off) are significantly associated with shorter OS (P = .002 and P < .001; respectively...Our analyses revealed that ALCAM serum levels may help to identify ENZA- and ABI-resistant patients and may thereby help to optimize future clinical decision-making.
DOI:
https://doi.org/10.1002/ijc.34159
